Acorda Therapeutics (NASDAQ:ACOR) had its price objective lowered by stock analysts at Leerink Swann to $18.00 in a note issued to investors on Wednesday, November 15th. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Swann’s target price would indicate a potential downside of 13.46% from the stock’s current price. Leerink Swann also issued estimates for Acorda Therapeutics’ Q1 2018 earnings at $0.69 EPS, Q2 2018 earnings at $0.84 EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.65) EPS, FY2018 earnings at $0.77 EPS and FY2019 earnings at ($2.18) EPS.
Several other brokerages also recently commented on ACOR. Zacks Investment Research downgraded Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 30th. Stifel Nicolaus reissued a “buy” rating on shares of Acorda Therapeutics in a research note on Friday, July 28th. ValuEngine raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. Janney Montgomery Scott reissued a “hold” rating and set a $18.00 target price on shares of Acorda Therapeutics in a research note on Wednesday, August 30th. Finally, CIBC began coverage on Acorda Therapeutics in a research note on Thursday, November 9th. They issued a “market perform” rating for the company. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Acorda Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $21.47.
Acorda Therapeutics (NASDAQ ACOR) opened at $20.80 on Wednesday. Acorda Therapeutics has a fifty-two week low of $13.60 and a fifty-two week high of $33.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77.
Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The firm had revenue of $141.07 million for the quarter, compared to the consensus estimate of $150.64 million. During the same period in the prior year, the company earned ($0.04) EPS. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. analysts forecast that Acorda Therapeutics will post -0.07 EPS for the current year.
Several institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in shares of Acorda Therapeutics during the 3rd quarter worth approximately $541,000. Convergence Investment Partners LLC bought a new position in shares of Acorda Therapeutics during the 3rd quarter worth approximately $1,294,000. OxFORD Asset Management LLP bought a new position in shares of Acorda Therapeutics during the 3rd quarter worth approximately $2,025,000. KBC Group NV boosted its holdings in shares of Acorda Therapeutics by 194.3% during the 3rd quarter. KBC Group NV now owns 64,007 shares of the biopharmaceutical company’s stock worth $1,514,000 after buying an additional 42,256 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Acorda Therapeutics by 11.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock worth $62,813,000 after buying an additional 283,091 shares in the last quarter.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/leerink-swann-lowers-acorda-therapeutics-inc-acor-price-target-to-18-00.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.